CRESCENT BIOPHARMA, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
CRESCENT BIOPHARMA, INC. (CBIO) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 565.54 thousand shares for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2015-08-06
- CRESCENT BIOPHARMA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-06-30 was 565.54K shares, a 7.55% decline year-over-year.
- CRESCENT BIOPHARMA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2014-06-30 was 611.70K shares.
- CRESCENT BIOPHARMA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2013-03-31 was 520.55K shares.
- CRESCENT BIOPHARMA, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2012 was 520.64K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|
| 2015-06-30 | 565.54K shares 10-Q · filed 2015-08-06 | 564.80K shares 10-Q · filed 2015-08-06 | |
| 2014-06-30 | 611.70K shares 10-Q · filed 2015-08-06 | 613.35K shares 10-Q · filed 2015-08-06 | |
| 2013-03-31 | 520.55K shares 10-Q · filed 2014-05-09 | ||
| 2012-12-31 | 520.64K shares 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |